1. Home
  2. ATYR vs LXFR Comparison

ATYR vs LXFR Comparison

Compare ATYR & LXFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • LXFR
  • Stock Information
  • Founded
  • ATYR 2005
  • LXFR 1898
  • Country
  • ATYR United States
  • LXFR United States
  • Employees
  • ATYR N/A
  • LXFR N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • LXFR Major Chemicals
  • Sector
  • ATYR Health Care
  • LXFR Industrials
  • Exchange
  • ATYR Nasdaq
  • LXFR Nasdaq
  • Market Cap
  • ATYR 327.0M
  • LXFR 380.9M
  • IPO Year
  • ATYR 2015
  • LXFR 2012
  • Fundamental
  • Price
  • ATYR $2.79
  • LXFR $10.65
  • Analyst Decision
  • ATYR Strong Buy
  • LXFR
  • Analyst Count
  • ATYR 6
  • LXFR 0
  • Target Price
  • ATYR $18.60
  • LXFR N/A
  • AVG Volume (30 Days)
  • ATYR 1.6M
  • LXFR 126.0K
  • Earning Date
  • ATYR 03-13-2025
  • LXFR 04-29-2025
  • Dividend Yield
  • ATYR N/A
  • LXFR 4.84%
  • EPS Growth
  • ATYR N/A
  • LXFR N/A
  • EPS
  • ATYR N/A
  • LXFR 0.68
  • Revenue
  • ATYR $235,000.00
  • LXFR $391,900,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • LXFR $2.26
  • Revenue Next Year
  • ATYR $873.22
  • LXFR $5.85
  • P/E Ratio
  • ATYR N/A
  • LXFR $15.70
  • Revenue Growth
  • ATYR N/A
  • LXFR N/A
  • 52 Week Low
  • ATYR $1.42
  • LXFR $9.26
  • 52 Week High
  • ATYR $4.66
  • LXFR $15.64
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 33.98
  • LXFR 27.55
  • Support Level
  • ATYR $3.20
  • LXFR $11.43
  • Resistance Level
  • ATYR $3.94
  • LXFR $11.94
  • Average True Range (ATR)
  • ATYR 0.22
  • LXFR 0.33
  • MACD
  • ATYR -0.09
  • LXFR -0.02
  • Stochastic Oscillator
  • ATYR 4.97
  • LXFR 1.18

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About LXFR Luxfer Holdings PLC

Luxfer Holdings PLC is a manufacturer industrial company innovating niche applications in materials engineering. It focuses on value creation by using its broad array of technical know-how and proprietary technologies to help create a safe, clean, and energy-efficient world. Luxfer's high-performance materials, components, and high-pressure gas containment devices are used in defense, first response and healthcare, transportation, and general industrial applications. It focuses on product lines related to magnesium alloys, zirconium chemicals, and carbon composites. Its segments are Elektron, Gas Cylinders, and Graphic Arts. It generates the majority of its revenue from Elektron and as well as Gas Cylinders.

Share on Social Networks: